MammaPrint® Provides Definitive Results, No Intermediates
Early-stage breast cancer patients, like you, want to have confidence in the treatment decisions you make with your physician. You want to know if you will benefit from chemotherapy for your breast cancer, or not. Receiving an intermediate or indeterminate result, will not provide you with the clarity you need.
Breast Cancer Diagnostic Testing
MammaPrint is a genomic test for women with early-stage breast cancer that helps predict clinical outcomes. MammaPrint identifies patients who, in the presence of a high risk clinical assessment, are unlikely to benefit from chemotherapy, sparing them from suffering unnecessary side effects and toxicity. MammaPrint is the only FDA cleared breast cancer recurrence assay designed for woman of all ages.
MammaPrint provides definitive “High Risk” or “Low Risk” results only, identifying 75% of the most commonly diagnosed breast cancer as Low Risk and safely to forego chemotherapy1, unlike other assays which may give an intermediate or indeterminate result. The Oncotype DX assay, for example, gives intermediate or indeterminate results 392-673 percent of the time.
Furthermore, MammaPrint is supported by the highest level of evidence (Level 1A) from the MINDACT study that was recently published in the New England Journal of Medicine.1
1Cardosa F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.
2Carlson JJ, Roth JA. The impact of the Oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Jul; 146(1): 233.
3Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373: 2005-14.